Dr. Arati Chand, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $49,782 | 23 | 53.7% |
| Food and Beverage | $30,770 | 1,478 | 33.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,970 | 4 | 4.3% |
| Education | $2,572 | 38 | 2.8% |
| Long term medical supply or device loan | $2,115 | 24 | 2.3% |
| Travel and Lodging | $1,817 | 9 | 2.0% |
| Unspecified | $882.55 | 1 | 1.0% |
| Honoraria | $750.00 | 2 | 0.8% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $21,052 | 96 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $15,161 | 137 | $0 (2024) |
| GENZYME CORPORATION | $10,908 | 33 | $0 (2024) |
| Incyte Corporation | $4,393 | 45 | $0 (2024) |
| PFIZER INC. | $3,728 | 129 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $3,625 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $3,559 | 57 | $0 (2024) |
| EMD Serono, Inc. | $3,546 | 25 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,776 | 56 | $0 (2024) |
| BeiGene USA, Inc. | $1,716 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,048 | 348 | AstraZeneca Pharmaceuticals LP ($14,635) |
| 2023 | $19,715 | 322 | AstraZeneca Pharmaceuticals LP ($5,459) |
| 2022 | $17,745 | 285 | GENZYME CORPORATION ($7,737) |
| 2021 | $7,210 | 180 | GlaxoSmithKline, LLC. ($2,947) |
| 2020 | $913.65 | 48 | AstraZeneca Pharmaceuticals LP ($96.07) |
| 2019 | $3,112 | 152 | PFIZER INC. ($248.03) |
| 2018 | $2,550 | 117 | Amgen Inc. ($362.28) |
| 2017 | $2,365 | 127 | Amgen Inc. ($417.14) |
All Payment Transactions
1,579 individual payment records from CMS Open Payments — Page 64 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/18/2017 | Helsinn Therapeutics (U.S.), Inc. | ALOXI (Drug), AKYNZEO | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: ONCOLOGY | ||||||
| 01/05/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $882.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 436 | 3,503 | $169,731 | $64,965 |
| 2022 | 21 | 556 | 3,284 | $205,624 | $76,646 |
| 2021 | 17 | 431 | 2,961 | $211,696 | $92,376 |
| 2020 | 15 | 451 | 905 | $178,924 | $66,533 |
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 84 | 261 | $70,941 | $26,258 | 37.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 26 | 100 | $30,723 | $12,357 | 40.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 48 | 79 | $15,002 | $5,211 | 34.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 11 | 44 | $6,160 | $4,224 | 68.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 18 | $6,612 | $2,635 | 39.8% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 20 | 100 | $6,137 | $2,433 | 39.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 25 | 81 | $5,347 | $2,172 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 43 | $7,898 | $2,163 | 27.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 35 | $5,193 | $2,116 | 40.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 51 | $3,223 | $1,328 | 41.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 20 | $2,861 | $1,080 | 37.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 42 | 109 | $1,433 | $824.88 | 57.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 20 | 24 | $2,824 | $748.34 | 26.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 46 | $1,690 | $658.31 | 39.0% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 12 | 29 | $1,280 | $527.64 | 41.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 1,170 | $638.30 | $110.01 | 17.2% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 17 | 1,256 | $1,669 | $89.52 | 5.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 16 | 37 | $99.38 | $29.16 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 239 | $68,015 | $25,589 | 37.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 26 | 113 | $36,599 | $14,643 | 40.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 53 | $15,317 | $6,132 | 40.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 62 | $13,578 | $5,472 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 69 | $13,919 | $4,437 | 31.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 25 | 103 | $7,186 | $2,827 | 39.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 12 | 40 | $6,300 | $2,539 | 40.3% |
About Dr. Arati Chand, M.D
Dr. Arati Chand, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/14/2009. The National Provider Identifier (NPI) number assigned to this provider is 1942434212.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arati Chand, M.D has received a total of $92,658 in payments from pharmaceutical and medical device companies, with $39,048 received in 2024. These payments were reported across 1,579 transactions from 98 companies. The most common payment nature is "Consulting Fee" ($49,782).
As a Medicare-enrolled provider, Chand has provided services to 1,874 Medicare beneficiaries, totaling 10,653 services with total Medicare billing of $300,521. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Los Angeles, CA
- Active Since 05/14/2009
- Last Updated 03/01/2024
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1942434212
Products in Payments
- IMFINZI (Biological) $10,234
- Fabhalta (Drug) $4,298
- BLENREP (Biological) $2,939
- ULTOMIRIS (Biological) $2,926
- SARCLISA (Biological) $2,924
- KISQALI (Drug) $2,663
- CALQUENCE (Drug) $2,568
- PADCEV (Biological) $1,848
- BRUKINSA (Drug) $1,716
- ENHERTU (Biological) $1,473
- KEYTRUDA (Biological) $1,261
- LIBTAYO (Biological) $1,094
- LYNPARZA (Drug) $982.43
- Stivarga (Drug) $977.39
- TAGRISSO (Drug) $914.07
- ZEJULA (Drug) $769.84
- OPDIVO (Biological) $744.76
- IMBRUVICA (Drug) $656.76
- GILOTRIF (Drug) $636.59
- REBLOZYL (Biological) $626.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Los Angeles
Dr. Sadeea Abbasi, M.d., Ph.d, M.D., PH.D
Student in an Organized Health Care Education/Training Program — Payments: $394,199
Dr. Edward Nomoto, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $376,152
Dr. Matthew Herrmann, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $248,245
Chanook Ahn, Dmd, DMD
Student in an Organized Health Care Education/Training Program — Payments: $233,441
Dr. Sina Tebi, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $226,858
Arjan Hura, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $188,267